Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Athenex stock

Learn how to easily invest in Athenex stock.

Athenex Inc
NASDAQ: ATNX - USD
$0.48
+ $0.0003 ( + 0.06%)
DRUG MANUFACTURERS-SPECIALTY & GENERIC

Athenex Inc is a drug manufacturers-specialty & generic business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 652 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Athenex

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATNX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Athenex stock price (NASDAQ: ATNX)

Use our graph to track the performance of ATNX stocks over time.

Athenex shares at a glance

Information last updated 2022-06-30.
Latest market close$0.49
52-week range$0.41 - $4.53
50-day moving average $0.51
200-day moving average $1.36
Wall St. target price$2.75
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.78

Buy Athenex shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Athenex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Athenex price performance over time

Historical closes compared with the close of $0.487 from 2022-07-05

1 week (2022-06-30) 19.07%
1 month (2022-06-03) -1.34%
3 months (2022-04-07) -41.40%
6 months (2022-01-06) -63.11%
1 year (2021-07-07) -87.92%
2 years (2020-07-07) -96.34%
3 years (2019-07-05) 19.6
5 years (2017-07-07) 18.42

Athenex financials

Revenue TTM $108.9 million
Gross profit TTM $37.8 million
Return on assets TTM -25.19%
Return on equity TTM -244.69%
Profit margin -176.47%
Book value $0.34
Market capitalisation $45.8 million

TTM: trailing 12 months

Athenex share dividends

We're not expecting Athenex to pay a dividend over the next 12 months.

Athenex share price volatility

Over the last 12 months, Athenex's shares have ranged in value from as little as $0.405 up to $4.525. A popular way to gauge a stock's volatility is its "beta".

ATNX.US volatility(beta: 0.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 0.9657. This would suggest that Athenex's shares are less volatile than average (for this exchange).

Athenex overview

Athenex, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors.

Frequently asked questions

What percentage of Athenex is owned by insiders or institutions?
Currently 13.147% of Athenex shares are held by insiders and 46.064% by institutions.
How many people work for Athenex?
Latest data suggests 652 work at Athenex.
When does the fiscal year end for Athenex?
Athenex's fiscal year ends in December.
Where is Athenex based?
Athenex's address is: Conventus Building, Buffalo, NY, United States, 14203
What is Athenex's ISIN number?
Athenex's international securities identification number is: US04685N1037
What is Athenex's CUSIP number?
Athenex's Committee on Uniform Securities Identification Procedures number is: 04685N103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site